| Literature DB >> 25568832 |
Leslie P Stone1, P Michael Stone1, Emily A Rydbom2, Lucas A Stone3, T Elliot Stone4, Lindsey E Wilkens5, Kathryn Reynolds6.
Abstract
A retrospective chart review analyzed the effect of customized nutrition on the incidence of pregnancy-induced hypertension (PIH), gestational diabetes (GDM), and small- and large-for-gestational-age (SGA, LGA) neonates, examining consecutive deliveries between January 1, 2011, and Decem ber 31, 2012, at a low-risk community hospital. The population was divided into 3 groups: (1) study group (SG), (2) private practice (PP), and (3) community healthcare clinic (CHCC). All groups received standard perinatal management, but additionally the study group was analyzed for serum zinc, carnitine, total 25-hydroxy cholecalciferol (25 OH-D), methylene tetrahydrofolate reductase, and catechol-O-methyl transferase polymorphisms in the first trimester prior to intervention, with subsequent second trimester and postpartum assessment of zinc, carnitine, and 25 OH-D after intervention. Intervention consisted of trimesterby-trimester nutrition and lifestyle education, supplementation of L-methyl folate, magnesium, essential fatty acids, and probiotics for all SG patients, with targeted supplementation of zinc, carnitine, and 25 OH-D. Because of small case occurrence rates of individual conditions in the study group, unreportable reductions were found, except GDM (SG vs CHCC, P value .046 with 95.38% confidence interval [CI]), and PIH (SG vs PP, P value .0505 with 94.95% CIl). The aggregated occurrence rate of the four conditions, however, was significantly lower in the study population than in either comparison population (PP P value .0154 with 98.46% CI, and CHCC P value .0265 with 97.35% CI). Customized nutritional intervention appears to have significantly reduced adverse perinatal outcomes. Prospective study within larger, at-risk populations is needed to determine whether customized nutrition improves conditions individually.Entities:
Keywords: Nutrition; neonatal complications; observational study; pregnancy
Year: 2014 PMID: 25568832 PMCID: PMC4268639 DOI: 10.7453/gahmj.2014.053
Source DB: PubMed Journal: Glob Adv Health Med ISSN: 2164-9561
Emphasis of Nutrition Education Classes
| Nutrients | Preconception | 1st Trimester | 2nd Trimester | 3rd Trimester | Postnatal |
|---|---|---|---|---|---|
| Adequate | Complete, carnitine, methionine, cysteine, 0.8 g/kg | Complete, adequate 1.1 g/kg | Complete, adequate 1.1 g/kg | Complete, adequate | |
| Essential fatty acids | Omega 3 | Omega 3 | Omega 3 | Omega 3 | |
| Complex | Complex | Complex, | fiber Complex | Complex | |
| Iodine, iron, magnesium, zinc, calcium, selenium | Iodine, selenium | Iron, magnesium, calcium | Iron, zinc, magnesium | Iron, calcium | |
| Methylation factors | Vitamins D, B6, B12, folate | Vitamins E, D, C | Vitamins C, A | B vitamins, vitamin D | |
| Full range of colors of fruits and vegetables | Colors: oxidative reserve | Colors: organ growth | Colors: newborn preference | Colors: oxidant balance | |
| Immune balance | Immune balance | Immune balance |
Prenatal Supplements Adjusted to Levels of Hemoglobin, Hematocrit, Mean Corpuscular Volume, Vitamin D, Zinc, Carnitine, and MTHFR Status
| Vitamin A mixed carotenoids | 5000 IU | Methylcobalamin | 800 µg | Chromium (chromium niacinate) | 200 µg |
| Vitamin C | 250 mg | Biotin | 100 µg | Molybdenum (molybdenum glycinate) | 25 µg |
| Vitamin D3 | 2000 IU | Pantothenic acid (d-calcium pantothenate) | 25 mg | Omega-3 fatty acids | 620 mg |
| Vitamin E (mixed) | 110 IU | Iron (iron bisglycinate) | 25 mg | EPA | 400 mg |
| Thiamine (mononitrate) | 5 mg | Iodine (potassium iodide) | 150 µg | DHA | 200 mg |
| Riboflavin (5 phosphate) | 5 mg | Zinc (zinc citrate) | 25 mg | Other omega-3 | 20 mg |
| Niacinamide | 25 mg | Selenium (L selenomethionine) | 100 µg | L-carnitine as 1492 mg L-carnitine tartrate | 1000 mg |
| B6 (Pyridoxal 5 phosphate) | 15 mg | Copper (copper gluconate) | 1.5 mg | Probiotic blend: | 60 B CFU |
| L-5-Methylfolate | 1000 µg | Manganese (manganese gluconate) | 5 mg |
Abbreviations: CFU, colony-forming unit; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; MTHFR, methylenetetrahydrofolate reductase.
Significant Differences in Pregnancy Complications in Clinic Populations (2-proportion z-test)
| Population (n) | Study vs Combined | Study vs Private | Study vs Community |
|---|---|---|---|
| Deliveries (664) | 111 vs 553 | 111 vs 322 | 111 vs 231 |
| Total complications (59) | 4 vs 55[ | 4 vs 33[ | 4 vs 22[ |
| Gestational diabetes mellitus (21) | 1 vs 20[ | 1 vs 10[ | 1 vs 10[ |
| Pregnancy-induced hypertension (28) | 2 vs 26[ | 2 vs 18[ | 2 vs 8[ |
| Large for gestational age (6) | 1 vs 5[ | 1 vs 1[ | 1 vs 4[ |
| Small for gestational age (4) | 0 vs 4[ | 0 vs 4[ | 0[ |
| NA |
Abbreviations: CI, confidence interval; NA, not available.
P<.05
P<.1
Power:
a = all case size low, so slightly under typical prerequisites
b = case size very low, moderately under statistic prerequisites
c = case size nonexistent, unsuitable for meaningful statistics
Comparitive Characteristics of Three Clinical Groups
| Characteristic | Study Group (111) | Private Practice (322) | Community Clinic (231) |
|---|---|---|---|
| Age | 29.7±5.68 | 29.8±2.72 | 27.6±2.91 |
| Gravidity | 2.97±1.76 | 2.72±1.58 | 2.91±1.74 |
| Parity | 1.13±1.17 | 1.10±1.08 | 1.31±1.38 |
| Race (%) | |||
| Caucasian | 93.3 | 90.8 | 58.4 |
| Hispanic | 5.0 | 8.6 | 41.6 |
| Smoking, alcohol, drug history (%) | 21.7 | 9.1 | 27.2 |
| Drug screen positive at birth (%) | 5.0 | 1.2 | 7.2 |
Body Mass Index (BMI) Descriptive Statistics Among Three Clinical Groups
| Statistic | Study Group | Private Practice | Community Clinic |
|---|---|---|---|
| Mean±SD | 24.8±5.3 | 24.1±5.4 | 26.1±5.6 |
| Minimum | 17.0 | 18.0 | 18.0 |
| First quartile | 21.0 | 20.5 | 21.0 |
| Median | 24.0 | 22.5 | 25.0 |
| Third quartile | 26.0 | 26.0 | 30.0 |
| Maximum | 54.0 | 42.0 | 39.0 |
| 25-30 | 33% | 24% | 27% |
| >30 | 11% | 10% | 24% |
Prevalence Comparisons of Gestational Diabetes Mellitus (GDM), Pregnancy-induced Hypertension (PIH), Large for Gestational Age (LGA), and Small for Gestational Age (SGA)
| Population (n) | GDM | PIH | LGA | SGA |
|---|---|---|---|---|
| Study group (n=111) | 1 (0.90%) | 2 (1.80%) | 1 (0.9%) | 0 |
| Private practice (n=322) | 10 (3.1%) | 18 (5.59%) | 1 (0.31%) | 4 (1.24%) |
| Community clinic (n=231) | 10 (4.3%) | 8 (3.46%) | 4 (1.73%) | 0 |
| Oregon | NA | NA | 9.4%[ | 6.1 %[ |
| US white/non-Hispanic | 5.6% | 7.5% | NA | NA |
| US Hispanic | 5.7% | 4.4% | NA | NA |
| United States[ | 5.7% | 6.7% | 6.9% | 7.9% |
| World[ | <7.5% | 7.5% | 9% | 23% |
Dalenius K, Bridley P, Smith B, Reinold C, Grummer-Stawn L. Pregnancy nutrition surveillance 2010 Report. Atlanta: US Department of Health and Human Services. Centers for Disease Control and Prevention; 2012.
2011 Pregnancy Nutrition Surveillance, Summary of Health Indicators. CDC www.cdc.gov/nccdphp/dnpa/PNSS.htm. Accessed October 22, 2014.
World Health Organization. Global burden of hypertensive disorders of pregnancy in the year 2000. http://www.who.int/healthinfo/statistics/bod_hypertensivedisordersofpregnancy.pdf. Accessed October 28, 2014.
World Health Organization. Diagnostic criteria and classification of hyperglycemia first detected in pregnancy. http://apps.who.int/iris/bit-stream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf?ua=1. Accessed October 28, 2014.
Chauhan SP, Grobman WA, Gherman RA, et al. Macrosomia in 23 developing countries: an analysis of a multicountry, facility-based, cross-sectional survey. Lancet. 2013; 381(9865):476-83.
deOnis M, Blossner M, Villar J. Levels and patterns of intrauterine growth retardation in developing countries. Eur J Clin Nutr. 1998;52 Suppl 1:55. Abbreviation: NA, not available.